Tinengotinib Clinical Trials

2 actively recruiting trials across 1 location

No change since May 2026

Also known as: TT-00420

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

TransThera Sciences (Nanjing), Inc.1
Memorial Sloan Kettering Cancer Center1

Indications

Cancer2
Prostate Cancer1
Breast Cancer1

Other1 trial

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Phase 2

New Haven, Connecticut1 trial

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Yale University (Data Collection Only)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.